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Abstract Vascular endothelial growth factor A (VEGFA)
has been extensively studied because of its role in follicular
development and is a principal angiogenic factor essential
for angiogenesis. Since vascularization of the theca layer
increases as follicles progress in size through preantral and
antral stages, VEGFA might influence follicle growth via
the regulation of angiogenesis. However, VEGFA might also
influence follicular development through nonangiogenic mech-
anisms, since its expression has been localized in nonvascular
follicles and cells. Alternative mRNA splicing of eight exons
from the VEGFA gene results in the formation of various
VEGFA isoforms. Each isoform has unique properties and is
identified by the number of amino acids within the mature
protein. Proangiogenic isoforms (VEGFA_XXX) are encoded
by exon 8a, whereas a sister set of isoforms (VEGFA_XXXB)
with antiangiogenic properties is encoded by exon 8b. The
antiangiogenic VEGFA_XXXB isoforms comprise the major-
ity of VEGFA expressed in most tissues, whereas expression of
the proangiogenic VEGFA isoforms is upregulated in tissues
undergoing active angiogenesis. Although proangiogenic and
antiangiogenic isoforms can now be distinguished from one
another, many studies evaluating VEGFA in ovarian and
follicular development up to now have not differentiated proan-
giogenic VEGFA from antiangiogenic VEGFA. Experiments
from our laboratory indicate that proangiogenic VEGFA pro-
motes follicle recruitment and early follicular development and
antiangiogenic VEGFA inhibits these processes. The balance
of proangiogenic versus antiangiognic VEGFA isoforms is thus
of importance during follicle development. Further studies are
warranted to elucidate the way that this balance regulates
follicular formation and progression.
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Introduction
Angiogenesis is the term used to describe the formation of new
vessels from the remodeling and expansion of the existing
vascular network. This process involves both proliferation
and migration of endothelial cells and can lead to the vascu-
larization of previously avascular tissues (Patan 2000; Shimizu
et al. 2003b). Ovarian and follicular vasculature enables the
delivery of nutrients, oxygen and systemic hormones and the
release of ovarian hormones (Robinson et al. 2009; Shimizu et
al. 2003b). Because of recurring cyclical changes and the
development of follicles, continued angiogenesis is essential
for these ovarian functions.
Follicle assembly and initial recruitment of primordial
follicles begins near the corticomedullary border and pro-
gresses outward to the periphery (Rajah et al. 1992; van
Wezel and Rodgers 1996). At this stage of development, the
major ovarian vessels are only located within the medulla
(Brennan et al. 2002). Primordial, primary and early sec-
ondary follicles are not directly supplied with vasculature
but are able to receive nutrients and oxygen by passive
diffusion from vessels in the surrounding stroma (Robinson
et al. 2009; Shimizu et al. 2003b; Suzuki et al. 1998).
Therefore, follicle assembly and growth at these stages
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might be influenced by close association with the vascula-
ture and the associated delivery of mediating factors.
In order for follicles to progress past these early devel-
opmental stages, an individual capillary network needs to
form around each follicle (Suzuki et al. 1998). Vasculariza-
tion is first visible in follicles that contain four layers
of granulosa cells (Wulff et al. 2001). All capillaries are
located outside of the basement membrane of the follicle
and granulosa cells remain avascular throughout follicle
development (Suzuki et al. 1998; Tamanini and De Ambrogi
2004). Proliferation of the theca layer significantly increases
from the early to late secondary follicle stage and approxi-
mately one quarter of these proliferating cells are endothelial
cells (Wulff et al. 2001). A significant increase in vascula-
ture has been demonstrated during preantral follicle devel-
opment in pigs (Martelli et al. 2006) and follicular blood
flow has been shown to be necessary for the continued
growth of small antral follicles in cows (Acosta et al.
2005). In rabbits, both vasodilation and extension of thecal
capillaries support the increase of blood flow during follicle
growth (Macchiarelli et al. 1993).
Vascular changes continue throughout preovulatory devel-
opment. In women, blood flow to the apical aspect of preovu-
latory follicles has been demonstrated to decrease, whereas
flow to the basal and lateral follicle walls remains unchanged.
Presumably, this change in blood flow is necessary for even-
tual follicle rupture (Brännström et al. 1998). Furthermore,
subcutaneous injection of adult rats with TNP-470, an angio-
genic inhibitor previously used to reduce tumor growth, not
only causes a reduction in follicular angiogenesis but also
prevents ovulation (Iijima et al. 2005).
In addition to regulating follicle development, alterations
in the follicular vasculature might also be involved in fol-
licular degeneration. Early indicators of follicular atresia
include a reduction in follicle vascularity and decreased
DNA synthesis in endothelial cells within the theca layer
(Greenwald 1989). In sheep, the capillary network in the
theca layer has been shown to undergo a significant reduc-
tion as atresia progresses (Hay et al. 1976). In humans, the
capillaries within atretic follicles are thin, have reduced
branching and are not uniformly distributed (Macchiarelli
et al. 1993).
Angiogenesis is a highly regulated process that involves
control from both proangiogenic and antiangiogenic factors.
Principal proangiogenic factors include vascular endothelial
growth factor A (VEGFA), fibroblast growth factor 2, mem-
bers of the platelet-derived growth factor family and angio-
poietins (Carmeliet 2000; Robinson et al. 2009). Of these
factors, VEGFA has been extensively studied in regard to its
role in angiogenic regulation (Ferrara 2004; Ferrara and
Davis-Smyth 1997) and has also been investigated as a
factor involved in follicular development. For example,
intraperitoneal injection of mature rats with VEGFA results
in increased numbers of preovulatory follicles, decreased
numbers of atretic follicles and increased numbers of ovulated
oocytes compared with control rats (Iijima et al. 2005). In
contrast, the subcutaneous administration of truncated ver-
sions of the VEGFA receptors, KDR (kinase insert domain
protein receptor) and FLT1 (FMS-like tyrosine kinase 1),
fused to IgG (Trap compounds that inhibit VEGFA) to adult
marmoset monkeys during the follicular phase inhibits ovula-
tion and results in twice as many atretic follicles compared
with control monkeys (Wulff et al. 2002). VEGFA might also
be necessary for increased oocyte competence, since the con-
centration of VEGFA protein in follicular fluid from antral
follicles is significantly greater in women that become preg-
nant after in vitro fertilization compared with those that do not
(Zhao et al. 2010).
VEGFA and its receptors
VEGFA (also known as VEGF) has been shown to promote
migration, proliferation and tube formation in endothelial
cells (Patan 2000) and is a member of the platelet-derived
growth factor and vascular endothelial growth factor
family. This family also includes placenta growth factor,
VEGFB, VEGFC and VEGFD (Ferrara 2004). VEGFA is
essential for both vasculogenesis and angiogenesis. Loss
of VEGFA in mouse models leads to severe vascular
abnormalities and is embryonic lethal between 11-12
days postcoitus (dpc; Carmeliet et al. 1996; Ferrara et
al. 1996). Messenger RNA expression for VEGFA is
prominently stimulated by hypoxia but VEGFA expression
is also upregulated by several other factors, such as platelet-
derived growth factor, insulin-like growth factor-1, tumor
necrosis factor-alpha, fibroblast growth factor, transforming
growth factor alpha and beta and epidermal growth factor
(Ferrara 2004; Robinson and Stringer 2001).
Two tyrosine kinase receptors bind VEGFA with high
affinity: FLT1 (also referred to as VEGFR1) and KDR (also
referred to as VEGFR2). Both of these receptors have seven
extracellular immunoglobulin-like domains, a single trans-
membrane region and an intracellular tyrosine kinase se-
quence with a kinase insert domain (Ferrara 2004;
Robinson and Stringer 2001). FLT1 was the first VEGFA
receptor identified and has a high affinity for VEGFA;
however, VEGFA binding results in only weak tyrosine
phosphorylation and does not appear to induce a prolifera-
tive response (de Vries et al. 1992; Park et al. 1994; See-
tharam et al. 1995; Waltenberger et al. 1994). Thus, FLT1
has been proposed to regulate VEGFA activity negatively
by sequestering it and limiting its availability to bind KDR
(Park et al. 1994). Mutant mice that lack FLT1 die between
8.5-9.5 dpc and display severe vascular disorganization and
an increased number of endothelial progenitor cells (Fong et
636 Cell Tissue Res (2012) 349:635–647
al. 1995, 1999). However, mutant mice that possess an
intact VEGFA-binding region on FLT1 but lack a tyrosine
kinase domain are able to develop fully and display normal
vascular development (Hiratsuka et al. 1998).
Although FLT1 has a higher affinity for VEGFA than
KDR, VEGFA binding to KDR induces stronger tyrosine
phosphorylation (Waltenberger et al. 1994). KDR is be-
lieved to mediate most, if not all, of VEGFA’s regulation
of endothelial cell proliferation and migration. Mutant mice
that lack KDR die between 8.5-9.5 dpc and fail to develop
organized blood vessels (Shalaby et al. 1995). Mutated
VEGFA proteins that lack affinity for the KDR receptor fail
to stimulate proliferation and migration of bovine endothe-
lial cell cultures. In contrast, treatment of these cell cultures
with VEGFA protein mutants that lack affinity for the FLT1
receptor stimulates endothelial cell proliferation similar to
that induced by treatment with wild-type VEGFA protein
(Keyt et al. 1996).
In addition to FLT1 and KDR, VEGFA has also been
shown to bind to neuropilins. Mutant mice that lack
neuropilin-1 (NRP1) die between 10.5-12.5 dpc with multi-
ple vascular defects and mutant mice that overexpress NRP1
die at 17.5 dpc with excessive and dilated vasculature
(Kawasaki et al. 1999; Kitsukawa et al. 1995). NRP1
appears to function as a coreceptor by presenting VEGFA
to KDR. NRP1 has an extremely short intracellular domain
and is unable to stimulate cellular responses in the absence
of KDR (Soker et al. 1998). NRP1 has also been shown to
bind directly to FLT1. Therefore, one of the mechanisms by
which FLT1 negatively regulates VEGFA activity might be
through competition for NRP1 binding (Fuh et al. 2000).
VEGFA isoforms
VEGFA is encoded by a single gene but various isoforms
exist because of alternative mRNA splicing of eight exons
(Fig. 1). The different isoforms are identified by their num-
ber of amino acids and each isoform has unique properties
(Houck et al. 1991; Tischer et al. 1991). Of the predominant
isoforms, VEGFA_121 (exons 1-5 and 8a; Fig. 1) is the
shortest protein and is unable to bind heparin. VEGFA_165
(exons 1-5, 7 and 8a; Fig. 1) and VEGFA_189 (exons 1-5, 6a,
7 and 8a; Fig. 1) contain additional amino acid sequences
encoded by exons 6 and 7. VEGFA_165 has moderate affinity
for heparin because of the amino acid residues encoded by
exon 7. VEGFA_189 has additional residues encoded by exon
6 and, thus, has a high affinity for heparin binding (Robinson
and Stringer 2001). VEGFA_189 is almost entirely bound to
either cell surfaces or the extracellular matrix (ECM), presum-
ably via interactions with heparin-containing proteoglycans.
Approximately 50%-70% of VEGFA_165 is bound to cells or
the ECM, whereas VEGFA_121 is freely diffusible (Houck et
al. 1992). NRP1 is able to bind to VEGFA_165 but not to
VEGFA_121. NRP1 enhances the binding of VEGFA_165 to
KDR and, thus, its regulation of the proliferation and migra-
tion of endothelial cells (Soker et al. 1998). Several other
isoforms have been isolated in different cells and species,
including VEGFA_115, VEGFA_145, VEGFA_162,
VEGFA_183 and VEGFA_206 (Anthony et al. 1994; Cheung
et al. 1995; Jingjing et al. 1999; Lange et al. 2003; Lei et al.
1998; Sugihara et al. 1998).
In addition to differences in amino acid length, VEGFA
isoforms have been identified that originate from alternative
splicing of exon 8. The previously described VEGFA iso-
forms are encoded by exon 8a (Fig. 1). Replacement of exon
8a with exon 8b generates a novel sister set of isoforms
(VEGFA_XXXB) referred to as the “B” isoforms (Fig. 1).
The VEGFA_XXXB isoforms only differ from the other
VEGFA isoforms by the six amino acids located at the C’-
terminal end and instead of being proangiogenic, the pres-
ence of residues encoded by exon 8b confers antiangiogenic
properties (Bates et al. 2002; Cui et al. 2004; Harper and
Bates 2008; Konopatskaya et al. 2006; Woolard et al. 2004).
In most normal adult tissues, the VEGFA_XXXB iso-
forms comprise at least half of the total VEGFA expressed.
In normal tissues undergoing active angiogenesis, such as
the placenta or in pathologic states, such as neoplasia,
VEGFA_XXXB isoform expression is downregulated
(Harper and Bates 2008; Woolard et al. 2004). For example,
mRNA for the VEGFA_165B isoform has been detected in
94.4% of normal kidney samples but only in 22.2% of renal
cell carcinoma samples from the same human patients
(Bates et al. 2002). Similarly, VEGFA_XXXB isoforms
comprise approximately 91% of the total amount of the
VEGFA mRNA amplified from normal colorectal tissue
Fig. 1 Alternate splicing of the human vascular endothelial growth
factor A (VEGFA) gene results in different VEGFA isoforms. Each
isoform is encoded by a specific set of exons and the resulting proteins
are named by their unique number of amino acids. Exon 8a encodes the
proangiogenic isoforms, whereas exon 8b encodes the antiangiogenic
“B” isoforms
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but less than 55% of the total mRNA from colorectal tumor
tissue from the same human patients (Varey et al. 2008).
Differential expression of the proangiogenic versus antian-
giogenic VEGFA isoforms is also evident in proliferative
diabetic retinopathy. This condition develops from hypoxia-
mediated blood vessel growth that extends from the retina
into the vitreous chamber in human diabetic patients. The
VEGFA_XXXB isoforms represent approximately 64% per-
cent of the VEGFA protein isolated from the vitreous of
non-diabetic human patients but only 12.5% of the VEGFA
protein isolated from the vitreous in diabetic patients (Bevan
et al. 2008). Therefore, alternate splicing of the VEGFA
gene and the resulting ratio of increased proangiogenic
versus antiangiogenic isoforms appears to be an important
regulator of angiogenesis.
The VEGFA_XXXB isoforms were considered as being
antiangiogenic shortly after their identification, because
treatment with VEGFA_165B inhibited VEGFA_165-medi-
ated proliferation and migration of cultured endothelial cells
(Bates et al. 2002). One study demonstrated that, whereas
VEGFA_165 could stimulate angiogenesis in rabbit corneas,
VEGFA_165B did not stimulate angiogenesis and could
even inhibit VEGFA_165-mediated corneal angiogenesis
(Woolard et al. 2004). In another study, intraocular injec-
tions of VEGFA_165B resulted in a nearly 50% reduction in
the area of hypoxia-induced retinal neovascularization in
mice (Konopatskaya et al. 2006). In addition, melanoma
cells expressing VEGFA_165B injected into nude mice
produced significantly smaller tumors than melanoma cells
expressing VEGFA_165 (Woolard et al. 2004).
The antiangiogenic properties of the VEGFA_XXXB
isoforms are believed to be related to the inefficient stimu-
lation of downstream signaling. VEGFA_165B has been
shown to bind to KDR with similar affinity as VEGFA_165
but does not activate downstream signaling via KDR.
Not only does treatment of human endothelial cells with
VEGFA_165B result in less KDR phosphorylation than
treatment with VEGFA_165 but VEGFA_165B-treated cells
demonstrate similar phosphorylation as untreated cells.
Treatment of these cells with both VEGFA_165 and
VEGFA_165B also results in less phosphorylation than treat-
ment with VEGFA_165 alone (Woolard et al. 2004). Another
study has demonstrated that VEGFA_165B is able to induce
phosphorylation by binding KDR but causes significantly less
phosphorylation at certain KDR sites, including one of the
positive mouse regulatory sites, Y1052. Furthermore,
VEGFA_165B is not able to bind NRP1 and this might
explain the ineffectiveness of these antiangiogenic VEGFA
at signaling upon binding to KDR (Kawamura et al. 2008).
The various VEGFA isoforms are named for the number
of amino acids that comprise each protein; however, the
number of amino acids for similar isoforms can vary be-
tween species. For example, the predominant proangiogenic
isoform in humans has 165 amino acids (VEGFA_165) but
the corresponding isoform in mice, rats and cattle consists in
only 164 amino acids (VEGFA_164; Bacic et al. 1995;
Breier et al. 1992; Robinson and Stringer 2001; Shimizu
and Miyamoto 2007). The antiangiogenic isoform that has
been the most extensively studied is human VEGFA_165B,
which has the same number of amino acids as its proangio-
genic counterpart, VEGFA_165 (Bates et al. 2002; Harper and
Bates 2008). We have sequenced the mRNA for VEG-
FA_164B (GenBank accession number EU017524.1) from
bovine granulosa cells. Based on the predicted amino acid
sequence, the antiangiogenic isoforms appear to have the
same number of amino acids as the proangiogenic isoforms
in the bovine. However, we have also sequenced the mRNA
for Vegfa_165b from rat ovaries and, based on the predicted
amino acid sequence, the antiangiogenic isoforms appear to
have an additional amino acid compared with their respective
proangiogenic isoforms in rats (Artac et al. 2009). To avoid
confusion, all VEGFA isoforms will be referred to, in this
paper, by using the number of amino acids found in humans
(e.g., VEGFA_121, VEGFA_164, VEGFA_189, VEG-
FA_165B) regardless of the species being discussed.
Establishment of the primordial follicle pool
In mammals, the oocyte population is primarily believed to
be nonrenewable and the number of primordial follicles
formed during fetal or early perinatal life is the factor that
limits the reproductive life span (Hansen et al. 2008;
McLaughlin and McIver 2009; Perez et al. 1999). A
decrease in the number of primordial follicles can result in
reduced fertility, premature ovarian failure, or sterility.
Exposure of fetal rats to gamma-irradiation severely
depletes the number of oocytes and premature ovarian fail-
ure occurs at approximately 6 months of age despite the
normal onset of puberty and initial fertility (Mazaud et al.
2002). In addition, the treatment of fetal rats with busulphan
results in a dose-dependent reduction in the number of
primordial follicles that develop in treated animals com-
pared with controls and severely depleted rats will exhaust
their supply of follicles early in adulthood (approximately
60 days of age; Hirshfield 1994).
During follicle assembly, approximately one third of the
oocytes are arrested at the diplotene stage of the first meiotic
division and are incorporated into primordial follicles,
whereas the remaining two thirds of germ cells are lost
through apoptosis (Pepling and Spradling 2001). Overex-
pression of the anti-apoptotic factor, BCL2 (B-cell leuke-
mia/lymphoma 2), in mouse ovaries leads to an increase in
the initial primordial follicle pool but this difference is lost
by 2 months of age (Flaws et al. 2001). Interestingly, loss of
BCL2 function in mice results in a dramatic reduction in the
638 Cell Tissue Res (2012) 349:635–647
number of normal primordial follicles and in the develop-
ment of numerous primordial follicle-like structures that
contain granulosa cells but lack an oocyte (Ratts et al.
1995). Furthermore, deletion of the pro-apoptotic factor,
BAX (BCL2-associated X protein), in mice also leads to
an increase in the initial primordial follicle pool and this
surplus is maintained into late adult life, resulting in sus-
tained ovarian function to nearly 2 years of age (Perez et al.
1999). Proangiogenic VEGFA isoforms are possibly in-
volved in stimulating the increase in BCL2 that promotes
germ cell survival. Although studies in females are lacking,
experiments utilizing 4-week-old bovine testes have dem-
onstrated a role for VEGFA in regulating germ cell death.
Increased numbers of germ cells together with increased
mRNA levels of BCL2 relative to BAX are seen after
VEGFA_165 treatment (Caires et al. 2009).
Previous studies in our laboratory have demonstrated
immunohistochemical staining for VEGFA protein and
VEGFA_XXXB isoforms in oocyte cysts and pregranulosa
cells of primordial follicles in embryonic and postnatal rat
ovaries. In addition, VEGFA_XXXB isoforms are also
localized to the oocytes of primordial follicles (Artac et al.
2009; McFee et al. 2009). The VEGFA receptors, FLT1 and
KDR, are localized to oocyte cysts and to both pregranulosa
cells and oocytes of primordial follicles (McFee et al. 2009).
Other studies have demonstrated weak VEGFA immunos-
taining of ooctyes in primordial follicles from human ova-
ries (Otani et al. 1999) and KDR expression has been
localized to oocytes of primordial follicles from goat ovaries
(Bruno et al. 2009).
Our laboratory has also demonstrated mRNA expression
for the Vegfa_121, Vegfa_165, Vegfa_189, Vegfa_165b and
Vegfa_189b isoforms in rat ovaries during late embryonic
and early postnatal development (Artac et al. 2009; McFee
et al. 2009). In contrast to male gonadal development,
distinct morphologic structures do not appear in the devel-
oping rat ovary until ovigerous cords form at the end of
gestation at approximately embryonic day 16-18 (∼E16-
E18). Oocytes are contained within these cord-like struc-
tures until postnatal day 1 (P1) when primordial follicles
begin to assemble (Fröjdman et al. 1993; Hirshfield and
DeSanti 1995; Rajah et al. 1992). Expression of mRNA
for the predominant proangiogenic isoform, Vegfa_165 and
its comparable antiangiogenic isoform, Vegfa_165b (Artac
et al. 2009; McFee et al. 2009) significantly increases be-
tween E13 and E18 in the rat ovary (Fig. 2a) and the timing
of this upregulation coincides with ovigerous cord forma-
tion. Therefore, the upregulation of angiogenic Vegfa and
the downregulation of antiangiogenic Vegfa_xxxb isoforms
might help to promote follicle assembly.
Systemic (IP) administration of adult mice with an anti-
body designed to neutralize VEGFA reduces the number of
primordial follicles by approximately 50% without having
an effect on primary or secondary follicles. Similar results
are seen with intrabursal administration of the same anti-
body to prepubertal (6- to 8-weeks-old) mice. Intrabursal
administration of a KDR antibody also reduces primordial
follicle numbers in prepubertal mice but injection with a
FLT1 antibody has no effect. Although these differences in
primordial follicles numbers are lost between 30 days
(immature mice) or 6 months (adults) after treatment (Roberts
et al. 2007), these data suggest that VEGFA and KDR play a
role in the maintenance of the primordial follicle pool.
Recruitment of primordial follicles
The duration of a female’s reproductive lifespan is deter-
mined not only by the number of primordial follicles that are
formed but also by the rate at which this pool of quiescent
follicles is depleted. Primordial follicles can remain quies-
cent or arrested in development for months to years to
decades, depending on the female’s normal reproductive
lifespan. A primordial follicle is defined as an individual
oocyte surrounded by a single layer of pregranulosa cells. A
primary follicle is characterized by a single layer of gran-
ulosa cells (Kezele et al. 2002; Parrott and Skinner 1999;
Smitz and Cortvrindt 2002). The transformation of flattened
pregranulosa to cuboidal granulosa cells is a relatively slow
process (taking longer than 4 months in humans) and fol-
licles are not considered to be actively growing until they
have reached the primary stage (Gougeon and Chainy 1987;
Smitz and Cortvrindt 2002). This transition is also an irre-
versible process and a follicle will continue to grow until its
eventual demise, either through atresia or ovulation.
Initial follicle recruitment begins near the corticomedul-
lary border (Hirshfield 1992; van Wezel and Rodgers 1996).
This is similar to the pattern that occurs during follicle
formation. Close association of recruited follicles to the
medulla might be related to these follicles being exposed
to factors diffusing from the medullary vasculature. The
total number of follicles within the pool has also been
proposed to influence the rate at which primordial follicles
are recruited. Administration of busulphan to pregnant rats
to destroy primordial germ cells in developing fetuses has
revealed an inverse correlation between the number of pri-
mordial follicles in the initial pool and the rate at which
these follicles are recruited to the growing pool (Hirshfield
1994). Morphometric studies have also demonstrated an
accelerated rate of follicle recruitment in women as they
approach menopause and their supply of primordial follicles
dwindles (Faddy et al. 1992; Gougeon et al. 1994; Hansen et
al. 2008; Richardson et al. 1987).
Several studies have investigated possible factors that are
involved in the regulation of primordial follicle recruitment.
Ovarian microarray analysis has revealed the upregulation
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of 148 genes and the downregulation of 50 genes in PO rat
ovaries cultured for 1 week which contain predominately
primary follicles when compared with freshly isolated P4
ovaries containing predominately primordial follicles. A
high proportion of primary follicles are found in cultured
ovaries, because the primordial to primary transition occurs
at a faster rate in culture (Kezele and Skinner 2003). One of
the 148 genes upregulated in this study was VEGFA. Quan-
titative polymerase chain reaction analysis has also identi-
fied the same increase in Vegfa gene expression (Kezele et
al. 2005).
One might assume that this upregulation of VEGFA has a
role in promoting the recruitment of primordial follicles into
the growing follicle pool. However, a similar study has
produced conflicting results. The culture of P4 rat ovaries
with AMH reduces the number of primordial follicles that
transition to the primary stage; however, microarray analysis
of these cultured ovaries has revealed an upregulation of
VEGFA (Nilsson et al. 2007). The results from this study
suggest that the upregulation of VEGFA has a role in sup-
pressing the recruitment of primordial follicles. One reason
for the conflicting results is that these studies do not distin-
guish which VEGFA isoforms are upregulated. Proangio-
genic VEGFA isoforms might be upregulated during the
primordial to primary follicle transition and the antiangio-
genic isoforms are possibly upregulated when this process is
suppressed. Indeed, studies in our laboratory with develop-
ing rat ovaries have shown that mRNA expression for both
Vegfa_165 and Vegfa_165b increases dramatically from E13
to E18. After birth, mRNA expression of both of these
Fig. 2 Quantitative reverse
transcription with the
polymerase chain reaction was
conducted to detect mRNA
levels for Vegfa_165,
Vegfa_165b, Vegfa_189 and
Vegfa_189b in rat ovaries from
embryonic day 13 (E13)
through postnatal day 5 (P5) of
ovarian development. Gapdh
(D-glyceraldehyde-3-phosphate
dehydrogenase) was used as an
endogenous control to account
for differences in starting
material. These data are the
result of at least three different
pools of tissue from each age
group. The mean normalized
values obtained for E13 have
been set at 1 and the values for
the other developmental ages
are presented as a fold-change
from E13. Therefore, values
greater than 1 indicate increased
mRNA levels and values less
than 1 indicate reduced mRNA
levels in comparison with E13
(a, b). The primary morpho-
logic stages that occur during
development of the rat ovary
from E13-P5 are presented in c
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isoforms declines (Artac et al. 2009; McFee et al. 2009).
However, Vegfa_165b expression dramatically declines to
levels less than those measured at E13, whereas Vegfa_165
expression rebounds from P0 to P5 (Fig. 2a). No trends are
apparent for the mRNA expression for either Vegfa_189 or
Vegfa_189b during these developmental time points (Fig. 2b).
Therefore, these data suggest that the upregulation of angio-
genic Vegfa and the downregulation of antiangiogenic
Vegfa_xxxb isoforms might help to promote follicle assembly
and early follicular recruitment.
Expression of VEGFA isoforms might be related to angio-
genesis of the ovary and/or follicles; however, both primordial
and primary follicles are avascular. Despite being avascular,
we have located VEGFA, VEGFA_XXXB isoforms, FLT1
and KDR in pregranulosa/granulosa cells of both of these
follicle types by using immunohistochemical staining of post-
natal rat ovaries. Protein expression for FLT1 and KDR has
also been localized to oocytes within these follicles (Artac et
al. 2009; McFee et al. 2009). Other studies have demonstrated
weak VEGFA immunostaining of oocytes in primary follicles
from adult rat ovaries (Celik-Ozenci et al. 2003). In goat
ovaries, KDR expression has been localized to oocytes of
primordial and primary follicles and to granulosa cells of
primary follicles (Bruno et al. 2009). These data provide
further support that VEGFA signaling plays a role in the
maintenance and/or activation of primordial follicles.
Experiments in our laboratory utilizing P3/4 rat ovary cul-
tures also support a role for VEGFA isoforms in initial follicle
recruitment. Treatment with a VEGFA receptor tyrosine kinase
inhibitor (blocks signal transduction through both FLT1 and
KDR) significantly reduces vascular density, increases the
percentage of primordial follicles and decreases the percentage
of developing follicles compared with control ovaries (Fig. 3;
McFee et al. 2009). In contrast, treatment with a NRP1 inhib-
itor (V1; Starzec et al. 2006) only minimally reduces vascular
density and does not alter the percent of primordial vs. growing
follicles in treated ovaries compared with controls (McFee et
al. 2009). However, the percentage of early primary follicles is
reduced and the percentage of primary follicles is increased
(Fig. 3; McFee et al. 2009). This suggests that VEGFA helps to
promote the activation of primordial follicles from the resting
state but that this regulation does not appear to require NRP1
Fig. 3 One ovary from postnatal day 3/4 rat was cultured for 2 weeks
with either recombinant VEGFA_165, antibodies to VEGFA_XXXB
isoforms, an inhibitor of KDR and FLT1 (VEGFA receptors), or an
inhibitor to NRP1. The paired ovary from each rat was cultured
without treatment to serve as a control. The mean number of follicles
at each stage of development was calculated as a percent of total
follicles and these percentages were compared between treated and
control ovaries (↑ significant increase in the percent of follicles at each
stage in treated ovaries in comparison with controls, ↓ significant
decrease in the percent of follicles at each stage in treated ovaries in
comparison with controls, - no difference in the percent of follicles at
each stage in treated ovaries in comparison with controls). All devel-
oping follicles include early primary, primary, transitional and second-
ary follicle stages
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binding, although VEGFA binding to NRP1 might help stim-
ulate the development of follicles to the primary state. Further-
more, the localization of VEGFA and its receptors to non-
vascular cells, together with the alterations of early follicular
development with and without reduced vascularization, indi-
cate that VEGFA regulation of follicle development does not
necessarily depend on vascular mechanisms.
Further experiments with the same P3/4 rat ovary culture
system demonstrated that treatment with recombinant
VEGFA_165 or a VEGFA_XXXB antibody (neutralizes all
antiangiogenic VEGFA isoforms) resulted in an increase in
vascular density. In addition, treated ovaries had a decreased
percentage of primordial follicles and an increased percentage
of developing follicles compared with controls (Fig. 3; Artac
et al. 2009). Both experiments lend further support for
VEGFA’s role in promoting follicle activation and early
development. However, neutralization of the antiangiogenic
VEGFA_XXXB isoforms produces more pronounced
changes than the administration of excess proangiogenic iso-
forms. This suggests that the antiangiogenic isoforms have a
prominent role in regulating follicle progression.
Other studies utilizing postnatal rat ovary cultures have
demonstrated a role for estrogen (E2) and progesterone (P4)
in initial follicle recruitment. Approximately half the num-
ber of primordial follicles transitioned to primary follicles in
PO rat ovary cultures that were treated with E2 or P4 com-
pared with control ovary cultures (Kezele and Skinner
2003). Circulating levels of E2 and P4 are high in the
developing embryonic and neonatal rat but drop substantial-
ly within 2 days after birth (Kezele and Skinner 2003;
Montano et al. 1995; Weisz and Ward 1980). In larger
mammals, steroid concentrations decrease around the same
time that follicles begin to develop (Thau et al. 1976). Taken
together, these data suggest that E2 and P4 can help prevent
premature primordial follicle recruitment in embryonic and
postnatal development (Kezele and Skinner 2003).
Another study supports this role of E2 and also suggests that
E2 regulates ovarian expression of VEGFA, which promotes
follicle recruitment. Intrabursal injection of diethylstilbestrol
(DES) in prepubertal (P21) rat pups significantly increases the
number of both primary and small secondary follicles in the
treated ovary compared with the contralateral ovary. Intrabursal
injection with recombinant VEGFA has similar effects on
follicle dynamics. In the same study, both systemic and intra-
bursal administration of E2 is shown to result in an increase in
ovarian VEGFA protein expression (Danforth et al. 2003).
Preantral and antral follicle development
The initiation of follicle growth is characterized by two
distinct phases. The first is the transition from primordial
to primary follicle at which time squamous pregranulosa
cells transform into cuboidal granulosa cells. The next phase
includes an increase in the number of granulosa cells to-
gether with an increase in oocyte size (Braw-Tal and Yossefi
1997). Secondary, or preantral, follicles are classified as an
oocyte surrounded by more than two granulosa cell layers
(Parrott and Skinner 1999). Complete zonae pellucidae de-
velop in large preantral follicles (Braw-Tal and Yossefi
1997). Early antral follicles have patchy, fluid-containing
spaces that lie between granulosa cells and follicles are
classified as antral, or tertiary, when the fluid spaces develop
into a larger cavity (Smitz and Cortvrindt 2002). In cattle,
antral formation first occurs in follicles with at least 250 gran-
ulosa cells in the largest histologic cross section (Braw-Tal and
Yossefi 1997). Theca cells initially begin to associate with
small preantral follicles but a distinct theca layer is only appar-
ent in late preantral or early antral follicles (Braw-Tal and
Yossefi 1997). The first theca cells form the theca interna layer
which is located closest to the granulosa cells and as develop-
ment progresses, a theca externa layer forms, which is highly
vascularized. It takes a few weeks for an antral cavity to
develop after initial follicle recruitment in mice and rats. The
same process takes approximately 2 months in humans and
several months in large domestic animals (Smitz andCortvrindt
2002).
Granulosa cells begin to develop follicle-stimulating hor-
mone (FSH) receptors during the preantral stage and theca
cells express luteinizing hormone (LH) receptors as soon as
they form (Roy et al. 1987; Smitz and Cortvrindt 2002;
Sokka et al. 1996). The follicles that are initially recruited
and begin development in the prepubertal period never
ovulate and are lost via atresia. Cyclic follicle recruitment
begins after puberty, because of the increase in circulating
FSH levels and ovulation of the first follicle coincides with
the first LH surge (Mazaud et al. 2002). During cyclic
recruitment, a cohort of antral follicles is able to escape
atresia because of the survival action of FSH (Chun et al.
1996; McGee and Hsueh 2000; Scheele and Schoemaker
1996). Loss of gonadotropins via hypophysectomy or folli-
cle culture without hormonal treatments eventually leads to
atresia and apoptosis of developing rat follicles (Chun et al.
1996; Nahum et al. 1996). FSH treatment but not LH or
human chorionic gonadotrophin (hCG) treatment, can sig-
nificantly prevent follicular atresia in cultured rat follicles
(Chun et al. 1996). Each growing follicle has a threshold
requirement for stimulation by FSH and this threshold needs
to be surpassed to achieve continued development. The
recruited cohort of follicles represents a group of follicles that
is at a comparable stage of development and, thus, has similar
developmental requirements (Fauser and Van Heusden 1997).
In postnatal rat ovaries, VEGFA, FLT1 and KDR have
been localized to granulosa cells, theca cells and the cyto-
plasm of oocytes of preantral follicles (McFee et al. 2009).
In postnatal mice with KDR-LacZ-expressing cells, KDR
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expression is also seen in granulosa cells, theca cells and the
cytoplasm of oocytes within secondary follicles (Bott et al.
2010). Other studies have also demonstrated strong VEGFA
immunostaining in secondary and antral follicles from rat
ovaries, especially in the theca cells (Celik-Ozenci et al.
2003). In an analysis of human ovaries, VEGFA has been
localized to theca interna cells throughout follicle develop-
ment and to granulosa cells after the primary stage (Yama-
moto et al. 1997). Another study has identified
immunostaining for VEGFA and FLT1 in the granulosa cells
of all developing follicles and in theca cells of medium and
large antral follicles (Otani et al. 1999). VEGFA protein is
also expressed in bovine fetal ovaries and is predominately
localized to blood vessels and secondary follicles. In adult
bovine ovaries, immunohistochemistry has localized
VEGFA expression to both theca and granulosa cells from
preovulatory follicles. KDR expression has been predomi-
nately located in granulosa cells but some expression is
present in theca cells (Berisha et al. 2000; Greenaway et
al. 2004).
Expression of mRNA for VEGFA_121, VEGFA_165,
VEGFA_189, FLT1 and KDR has also been demonstrated
in fetal bovine ovaries and levels of VEGFA_121 and
VEGFA_189 increase as development proceeds. Messenger
RNA levels for VEGFA are consistent across follicle devel-
opment in theca cells, whereas the expression of KDR and
FLT1 is weak in granulosa cells but strong in theca cells
(Yang and Fortune 2007). Both granulosa and theca cells in
developing follicles from adult bovine and porcine ovaries
express mRNA for the VEGFA_165 and VEGFA_121 iso-
forms and the expression of VEGFA increases as antral
follicles increase in size (Berisha et al. 2000; Mattioli et al.
2001). Cultured bovine granulosa cells predominately ex-
press the VEGFA_120 and VEGFA_164 isoforms but also
weakly express mRNA for VEGFA_189. These cultured
cells additionally express mRNA for KDR (Greenaway et
al. 2004). In marmoset monkeys, mRNA for VEGFA is
expressed in both granulosa and theca cells of secondary
and tertiary follicles, whereas FLT1 and KDR are expressed
by the endothelial cells within the theca layer in marmoset
monkeys. The mRNA levels for VEGFA in granulosa cells
increase from the secondary follicle stage to the tertiary
stage (Wulff et al. 2001, 2002).
VEGFA protein in follicular fluid and granulosa cells has
been demonstrated to increase in both bovine and porcine
follicles as they increase in size from small to large antral
follicles (Berisha et al. 2000; Greenaway et al. 2004;
Mattioli et al. 2001). Protein levels of KDR also increase
significantly between small and large bovine antral follicles
and protein levels in theca cells are similar to those in
granulosa cells from large antral follicles (Greenaway et al.
2004). Medium antral follicles from gilts have distinct dif-
ferences in VEGFA protein expression. Those follicles with
high follicular fluid concentrations of VEGFA also have
high follicular fluid levels of E2 and wider vascular net-
works within the follicular wall than medium follicles with
low VEGFA levels (Mattioli et al. 2001).
Based upon mRNA and protein expression alone,
VEGFA appears to be involved in the growth of follicles
from the preantral and early antral stages to later antral
stages. Numerous other studies have added support for the
role of VEGFA in follicle development. Culturing pieces of
bovine fetal ovarian cortex in the presence of VEGFA has
no effect on the number of primordial or primary follicles
but does increase the number of secondary follicles (Yang
and Fortune 2007). Injection of VEGFA gene fragments into
the ovaries of miniature gilts results in increased numbers of
large antral follicles, increased mRNA expression of the
VEGFA_165 and VEGFA_121 isoforms in granulosa cells
and increased VEGFA protein levels in follicular fluid. In
addition, the capillary density within the theca interna is
increased in follicles from VEGFA-injected gilts compared
with control animals (Shimizu 2006; Shimizu et al. 2003a).
Intramuscular injection of prepubertal gilts with eCG indu-
ces an increase in VEGFA protein levels in follicular fluid
and VEGFA mRNA levels in granulosa cells of follicles
larger than 4 mm in diameter (Barboni et al. 2000). VEGFA
treatment also results in an increased number of preovula-
tory follicles, a decreased number of atretic follicles and an
increased number of ovulated oocytes (Iijima et al. 2005).
VEGFA regulation of preantral and antral follicle growth
appears to be mediated through FLT1 and KDR signaling.
Inhibition of VEGFA with intrabursal injection of a soluble
FLT1/Fc chimera Trap does not alter the number of preantral
or early antral follicles in prepubertal rats treated with eCG.
However, the number of atretic follicles increases compared
with control rats, together with increased BAX and de-
creased BCL2 protein levels in follicular cells (Abramovich
et al. 2006). Neutralization of VEGFA by the administration
Fig. 4 Representation of the proposed role for VEGFA isoforms in
follicle development. Proangiogenic isoforms appear to promote initial
recruitment and development of ovarian follicles, whereas antiangio-
genic isoforms appear to suppress these processes
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of a VEGF Trap (truncated versions of FLT1 or FLT1 and
KDR fused to IgG) significantly reduces granulosa cell pro-
liferation, theca proliferation and thecal vascularization in
secondary and tertiary follicles in marmoset monkeys (Wulff
et al. 2001, 2002).
Concluding remarks
A strong body of evidence supports a role for VEGFA in
initial follicle recruitment and development. Even though
VEGFA is considered a prominent proangiogenic factor,
VEGFA has been localized to nonvascular follicles and cells
and might influence follicular development via nonvascular
mechanisms. In addition, VEGFA isoforms have now been
identified that have antiangiogenic properties (Harper and
Bates 2008). Specific agents have been developed that differ-
entiate between the antiangiogenic and proangiogenic
VEGFA isoforms; however, many of the studies evaluating
VEGFA in regard to ovarian and follicular development up
until this point have not differentiated proangiogenic VEGFA
from antiangiogenic VEGFA. One must take this into consid-
eration when interpreting the findings from these studies. In
vitro experiments from our laboratory indicate that proangio-
genic VEGFA promotes, whereas antiangiogenic VEGFA
suppresses follicle recruitment and early follicular develop-
ment (Fig. 4). Further studies are warranted to elucidate the
way in which the different VEGFA isoforms regulate follicu-
lar formation and progression. In vivo experiments utilizing
cell-specific mutant models that lack or overexpress proangio-
genic and antiangiogenic isoforms will further define the role
of VEGFA in these processes and aid our understanding of the
balance of proangiogenic versus antiangiogenic VEGFA iso-
forms in follicular development.
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tive Commons Attribution License which permits any use, distribution
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